Global Antibody Drug Conjugate Market Outlook 2020
Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a “magic bullet” to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.
According to this edition of the report “Global Antibody Drug Conjugate Market Outlook 2020”, the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.
Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry’s growth.
The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
According to this edition of the report “Global Antibody Drug Conjugate Market Outlook 2020”, the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.
Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry’s growth.
The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. ANTIBODY DRUG CONJUGATE (ADC) - AN INTRODUCTION
4. ADC MARKET OUTLOOK TO 2020
4.1 ADCETRIS
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2020
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2020
5. ADC PIPELINE ANALYSIS
5.1 By Phase
5.2 By Indication
5.3 By Drug
6. DRIVERS AND CHALLENGES
6.1 Drivers
6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
6.1.2 Efforts towards Patent Protection to Drive ADC Market
6.2 Challenges
6.2.1 Production Hurdles and Cost
6.2.2 Inadequacy of Experienced Manufacturers
6.2.3 Regulatory Challenges
7. CURRENT STATUS OF POTENTIAL ADCS IN PIPELINE
7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
7.3 Indatuximab Ravtansine/BT-062 - Biotest
7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer
8. TRENDS AND DEVELOPMENTS
8.1 ADC at the Forefront to Treat Hematological Malignancies
8.2 ADCs Providing Advantages to Breast Cancer Patients
9. STRATEGIC COLLABORATIONS IN THE ADC INDUSTRY
10. COMPETITIVE ASSESSMENT
10.1 Seattle Genetics
10.2 Roche
10.3 Immunogen, Inc.
10.4 Bayer Healthcare
10.5 Novartis
10.6 Immunomedics
10.7 Agensys, Inc
2. RESEARCH METHODOLOGY
3. ANTIBODY DRUG CONJUGATE (ADC) - AN INTRODUCTION
4. ADC MARKET OUTLOOK TO 2020
4.1 ADCETRIS
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2020
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2020
5. ADC PIPELINE ANALYSIS
5.1 By Phase
5.2 By Indication
5.3 By Drug
6. DRIVERS AND CHALLENGES
6.1 Drivers
6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
6.1.2 Efforts towards Patent Protection to Drive ADC Market
6.2 Challenges
6.2.1 Production Hurdles and Cost
6.2.2 Inadequacy of Experienced Manufacturers
6.2.3 Regulatory Challenges
7. CURRENT STATUS OF POTENTIAL ADCS IN PIPELINE
7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
7.3 Indatuximab Ravtansine/BT-062 - Biotest
7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer
8. TRENDS AND DEVELOPMENTS
8.1 ADC at the Forefront to Treat Hematological Malignancies
8.2 ADCs Providing Advantages to Breast Cancer Patients
9. STRATEGIC COLLABORATIONS IN THE ADC INDUSTRY
10. COMPETITIVE ASSESSMENT
10.1 Seattle Genetics
10.2 Roche
10.3 Immunogen, Inc.
10.4 Bayer Healthcare
10.5 Novartis
10.6 Immunomedics
10.7 Agensys, Inc
LIST OF FIGURES
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2014-2020
Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global - ADCETRIS Market (Billion US$), 2014-2020
Figure 4-4: Global - Kadcyla Market (Billion US$), 2014-2020
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2014-2020
Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global - ADCETRIS Market (Billion US$), 2014-2020
Figure 4-4: Global - Kadcyla Market (Billion US$), 2014-2020
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)
LIST OF TABLES:
Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 7-1: ADCs in Pipeline
Table 9-1: Strategic Collaborations in ADC Industry
Table 10-1: Top Companies by ADCs in Pipeline (2014)
Table 10-2: Seattle Genetics - ADCs in Pipeline
Table 10-3: Seattle Genetics - ADCs Collaborator Pipeline
Table 10-4: Seattle Genetics - Strengths and Weaknesses
Table 10-5: Roche - ADC Collaborator Pipeline
Table 10-6: Roche - Strengths and Weaknesses
Table 10-7: Immunogen, Inc. - ADCs in Pipeline
Table 10-8: Immunogen, Inc. - ADC Collaborator Pipeline
Table 10-9: Immunogen, Inc. - Strengths and Weaknesses
Table 10-10: Bayer Healthcare - ADCs in Pipeline
Table 10-11: Bayer Healthcare - Strengths and Weaknesses
Table 10-12: Novartis Pharmaceuticals - ADCs in Pipeline
Table 10-13: Novartis Pharmaceuticals - Strengths and Weaknesses
Table 10-14: Immunomedics - ADCs in Pipeline
Table 10-15: Immunomedics - Strengths and Weaknesses
Table 10-16: Agensys, Inc. - ADC Collaborator Pipeline
Table 10-17: Agensys, Inc. - Strengths and Weaknesses
Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 7-1: ADCs in Pipeline
Table 9-1: Strategic Collaborations in ADC Industry
Table 10-1: Top Companies by ADCs in Pipeline (2014)
Table 10-2: Seattle Genetics - ADCs in Pipeline
Table 10-3: Seattle Genetics - ADCs Collaborator Pipeline
Table 10-4: Seattle Genetics - Strengths and Weaknesses
Table 10-5: Roche - ADC Collaborator Pipeline
Table 10-6: Roche - Strengths and Weaknesses
Table 10-7: Immunogen, Inc. - ADCs in Pipeline
Table 10-8: Immunogen, Inc. - ADC Collaborator Pipeline
Table 10-9: Immunogen, Inc. - Strengths and Weaknesses
Table 10-10: Bayer Healthcare - ADCs in Pipeline
Table 10-11: Bayer Healthcare - Strengths and Weaknesses
Table 10-12: Novartis Pharmaceuticals - ADCs in Pipeline
Table 10-13: Novartis Pharmaceuticals - Strengths and Weaknesses
Table 10-14: Immunomedics - ADCs in Pipeline
Table 10-15: Immunomedics - Strengths and Weaknesses
Table 10-16: Agensys, Inc. - ADC Collaborator Pipeline
Table 10-17: Agensys, Inc. - Strengths and Weaknesses
